Korean J Urol Oncol.
2018 Dec;16(3):97-102. 10.22465/kjuo.2018.16.3.97.
Precision Medicine in Castration-Resistant Prostate Cancer
- Affiliations
-
- 1Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea. sjyun@chungbuk.ac.kr, wjkim@chungbuk.ac.kr
- 2Department of Urology, Chungbuk National University Hospital, Cheongju, Korea.
- KMID: 2438602
- DOI: http://doi.org/10.22465/kjuo.2018.16.3.97
Abstract
- Prostate cancer is usually managed by androgen deprivation therapy after failure of primary treatment. However, such therapies are only temporarily effective in prostate cancer patients, and the most patients experience the progression to castration-resistant prostate cancer (CRPC). Docetaxel chemotherapy is conventional effective treatment for CRPC but has many adverse effects. In CRPC patients, treatment decisions were not typically base on the recognitions of inter-individual differences. Therefore, there are growing interests for precision medicine in CRPC. In this review, we summarized the precision medicine such as candidate target genes and potential therapies in CRPC.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Chemotherapy With Androgen Deprivation for Hormone-Naïve Prostate Cancer
- Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations
- New Androgen Receptor Axis-Targeted Agents inthe Treatment of Nonmetastatic Castration-ResistantProstate Cancer: From Bench to Clinical Trials
- Long-Lasting Antiandrogen Withdrawal Syndrome in Castration-Resistant Prostate Cancer: Three Cases With Complete Response
- Hormonal therapy and chemotherapy for advanced prostate cancer
